References
- Generini S., Matucci‐Cerinic M. Raynaud's phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 1999; 455: 93–100
- de Oliveira N. C., dos Santos Sabbag L. M., Ueno L. M., de Souza R. B., Borges C. L., de Sá Pinto A. L., et al. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement. Scand J Rheumatol 2007; 36: 458–61
- Distler O., Del Rosso A., Giacomelli R., Cipriani P., Conforti M. L., Guiducci S., et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4: R11
- Wenger R. H. Cellular adaptation to hypoxia: O2‐sensing protein hydroxylases, hypoxia‐inducible transcription factors, and O2‐regulated gene expression. FASEB J 2002; 16: 1151–62
- Abraham D., Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007; 9(Suppl 2): S2
- Takagi K., Kawaguchi Y., Hara M., Sugiura T., Harigai M., Kamatani N. Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol 2003; 134: 538–44
- Allanore Y., Wipff J., Kahan A., Boileau C. Genetics of systemic sclerosis. Joint Bone Spine 2007; 74: 577–83
- Tanimoto K., Yoshiga K., Eguchi H., Kaneyasu M., Ukon K., Kumazaki T., et al. Hypoxia‐inducible factor‐1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003; 24: 1779–83
- Resar J. R., Roguin A., Voner J., Nasir K., Hennebry T. A., Miller J. M., et al. Hypoxia inducible factor 1alpha polymorphism and coronary collaterals in patients with ischemic heart disease. Chest 2005; 128: 787–91
- Leroy E. C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T. A., Jr, et al. Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 1988; 15: 202–5
- Dieudé P., Guedj M., Wipff J., Avouac J., Hachulla E., Diot E., Granel B., et al. The PTPN22 620w allele confers susceptibility to systemic sclerosis: a large case–control study among European Caucasians and meta‐analysis. Arthritis Rheum 2008; 58: 2183–8
- Denton C. P., Black C. M., Abraham D. J. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2: 134–44
- Wipff J., Avouac J., Borderie D., Zerkak D., Lemarechal H., Kahan A., et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) 2008; 47: 972–5
- Morahan G., Huang D., Wu M., Holt B. J., White G. P., Kendall G. E., et al. Association of IL12B promoter polymorphism with severity of atopic and non‐atopic asthma in children. Lancet 2002; 360: 455–9